Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

about

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

Item

http://www.wikidata.org/entity/Q58698992

description

scientific article published on 25 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Preventing and treating brain ...... ced non-small cell lung cancer

@en

Preventing and treating brain ...... ced non-small cell lung cancer

@nl

type

Item

label

Preventing and treating brain ...... ced non-small cell lung cancer

@en

Preventing and treating brain ...... ced non-small cell lung cancer

@nl

prefLabel

Preventing and treating brain ...... ced non-small cell lung cancer

@en

Preventing and treating brain ...... ced non-small cell lung cancer

@nl

P1476

Preventing and treating brain ...... ced non-small cell lung cancer

@en

P2093

Chung-Liang Ho

http://www.w3.org/2001/XMLSchema#string

Po-Lan Su

http://www.w3.org/2001/XMLSchema#string

Szu-Chun Yang

http://www.w3.org/2001/XMLSchema#string

Wei-Yuan Chang

http://www.w3.org/2001/XMLSchema#string

Wu-Chou Su

http://www.w3.org/2001/XMLSchema#string

Wu-Wei Lai

http://www.w3.org/2001/XMLSchema#string

Yau-Lin Tseng

http://www.w3.org/2001/XMLSchema#string

Yi-Lin Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.

P304

1758835918797589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758835918797589

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chien-Chung Lin

P577

2018-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30263066

http://www.w3.org/2001/XMLSchema#string

P932

6156208

http://www.w3.org/2001/XMLSchema#string